Browse the corpus

Antibiotics are among the most transformative developments in modern medicine, drastically reducing morbidity and mortality from bacterial infections. However, their benefits are tempered by potential adverse effects (eg, gastrointestinal disturbances, allergic reactions, Clostridioides difficile infection). Such risks are justifiable only when antibiotics are truly needed; unnecessary use provides no benefit and incurs harm. A critical consequence of the inappropriate use of antibiotics is the emergence of antimicrobial resistance (AMR). Antibiotic exposure exerts selective pressure on bacterial populations, thereby facilitating resistance through genetic changes (eg, mutation and gene amplification) and horizontal gene transfer. Resistant organisms can spread via direct contact, healthcare environments, or community transmission, affecting even those without prior antibiotic exposure. Participation in this course strengthens clinicians' competency in antimicrobial stewardship principles that optimize antibiotic selection, dosing, route, and duration across common clinical scenarios. Content emphasizes timely empiric therapy when indicated, structured reassessment with de-escalation based on culture and susceptibility results, and use of rapid diagnostics to accelerate targeted treatment. Institutional antimicrobial stewardship programs play a crucial role in promoting responsible antibiotic use, enhancing patient safety, and mitigating the spread of antibiotic resistance. These programs involve coordinated efforts by clinicians, pharmacists, infection control experts, and healthcare administrators. Strengthening interprofessional collaboration among prescribers, pharmacists, and infection control teams is essential to reduce inappropriate prescribing and mitigate the global impact of AMR. Objectives: Assess the role of antibiotic resistance in treating bacterial infections, including their impact on morbidity and mortality. Determine the consequences of inappropriate antibiotic use, such as adverse drug reactions and the development of resistance, and reinforce the importance of evidence-based prescribing. Identify current antimicrobial stewardship guidelines and how they apply to clinical practice to reduce antimicrobial resistance.

Assess the role of antibiotic resistance in treating bacterial infections, including their impact on morbidity and mortality. Determine the consequences of inappropriate antibiotic use, such as adverse drug reactions and the development of resistance, and reinforce the importance of evidence-based prescribing. Identify current antimicrobial stewardship guidelines and how they apply to clinical practice to reduce antimicrobial resistance. Determine the role of the interprofessional healthcare team in implementing stewardship strategies to optimize antibiotic use and preserve long-term antimicrobial effectiveness. Access free multiple choice questions on this topic.

Antibiotic resistance is the capacity of bacteria to survive and proliferate despite exposure to antibiotics that would typically inhibit their growth or eliminate them. Resistance develops through various mechanisms, including genetic mutations, production of enzymes that degrade antibiotics, efflux pumps, horizontal gene transfer, and adaptive physiological changes. Resistance is typically identified through in vitro susceptibility testing. As a component of broader antimicrobial resistance (AMR), antibiotic resistance leads to treatment failure, prolonged illness, and heightened mortality worldwide.[1][CDC. About antimicrobial resistance. 2025][ECDC. Antimicrobial resistance (AMR). 2025] Results from a 2016 national study estimated that approximately 30% of outpatient antibiotic prescriptions were inappropriate, underscoring widespread prescribing inefficiencies.[2] As of 2022, Centers for Disease Control and Prevention (CDC) surveillance data show that nearly 28% of outpatient antibiotic prescriptions are unnecessary. Moreover, 29.5% of these prescriptions involved broad-spectrum antibiotics classified under the World Health Organization (WHO) Watch category (from Access, Watch, Reserve antibiotic guidance), which are associated with a high risk of promoting resistance.[CDC. Core Elements of Hospital Antibiotic Stewardship Programs. 2025][CDC Antibiotic Use and Stewardship in the United States, 2024 Update: Progress and Opportunities. 2024] To address these challenges, antimicrobial stewardship programs have been widely endorsed by major health organizations, including the CDC, the Infectious Diseases Society of America, and the Society for Healthcare Epidemiology of America.[3][CDC. Core Elements of Hospital Antibiotic Stewardship Programs. 2025] These programs focus on optimizing antibiotic use through evidence-based prescribing protocols, interprofessional collaboration, and systematic review and auditing of prescribing practices. Epidemiology Globally, antibiotic resistance is escalating rapidly. In 2021, bacterial antimicrobial resistance was linked to an estimated 4.71 million deaths, including 1.14 million directly caused by resistant infections.[4] While AMR-related mortality has decreased among children younger than 5, adults older than 70 have had more than an 80% increase in deaths attributed to AMR during the same timeframe.[4]

Globally, antibiotic resistance is escalating rapidly. In 2021, bacterial antimicrobial resistance was linked to an estimated 4.71 million deaths, including 1.14 million directly caused by resistant infections.[4] While AMR-related mortality has decreased among children younger than 5, adults older than 70 have had more than an 80% increase in deaths attributed to AMR during the same timeframe.[4] There is growing concern about increasing resistance in gram-negative pathogens, a paucity of new antibiotics in development, and the risk of significant adverse effects with existing antibiotics.[5] Antibiotic consumption has also grown substantially, from 29.5 billion to 34.3 billion defined daily doses between 2016 and 2023, a 16.3% increase.[6] This trend is most pronounced in low- and middle-income countries and is closely linked to inappropriate prescribing and over-the-counter antibiotic use. Antimicrobial resistance places a massive financial strain on global healthcare systems, costing tens of billions of United States (US) dollars each year. If current trends continue, this figure is expected to surge into the hundreds of billions annually within the next 10 years. For instance, the World Bank projects up to $159 billion in yearly impact by 2050, while the O’Neill Review foresees a cumulative global loss of approximately $100 trillion by mid-century if no action is taken.[7][8][9] The estimated cost per individual resistant infection ranges from $100 to more than $20,000, depending on the pathogen and setting, as well as broader economic losses from reduced productivity and premature deaths.[10]

Antimicrobial resistance places a massive financial strain on global healthcare systems, costing tens of billions of United States (US) dollars each year. If current trends continue, this figure is expected to surge into the hundreds of billions annually within the next 10 years. For instance, the World Bank projects up to $159 billion in yearly impact by 2050, while the O’Neill Review foresees a cumulative global loss of approximately $100 trillion by mid-century if no action is taken.[7][8][9] The estimated cost per individual resistant infection ranges from $100 to more than $20,000, depending on the pathogen and setting, as well as broader economic losses from reduced productivity and premature deaths.[10] In the US, hospital-onset resistant infections increased by approximately 20% between 2021 and 2022, following the COVID-19 pandemic.[CDC. Antimicrobial Resistance Facts and Stats. 2025]. Particularly concerning is the emergence of Candida auris, a multidrug-resistant fungus, and cases have increased 5-fold since 2019.[11][CDC. Antimicrobial Resistance Facts and Stats. 2025.][CDC. About antimicrobial resistance. 2025][ECDC. Antimicrobial resistance (AMR). 2025] Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp (ESKAPE pathogens) remain major causes of hospital-acquired infections and show rising resistance trends in some regions (eg, China).[12] Each year, more than 2.8 million antibiotic-resistant infections and over 35,000 related deaths occur in the US, mirroring global trends (see Table 1).[13][CDC. Antibiotic Resistance Threats in the United States, 2019. 2019] Without effective intervention, AMR is projected to claim up to 10 million lives annually by 2050, potentially totaling 39 million deaths over the next 25 years.[14] Global surveillance efforts are expanding in response to this threat. The WHO Global Antimicrobial Resistance Surveillance System, launched in 2015, provides standardized international data on antimicrobial resistance trends to inform policy. In 2024, the United Nations General Assembly reaffirmed worldwide commitments to stewardship, innovation, and equitable access to effective antimicrobials.[15][WHO. Global antibiotic resistance surveillance report 2025. 2025] [CDC. Antibiotic Resistance Threats in the United States, 2019. 2019] Table

Global surveillance efforts are expanding in response to this threat. The WHO Global Antimicrobial Resistance Surveillance System, launched in 2015, provides standardized international data on antimicrobial resistance trends to inform policy. In 2024, the United Nations General Assembly reaffirmed worldwide commitments to stewardship, innovation, and equitable access to effective antimicrobials.[15][WHO. Global antibiotic resistance surveillance report 2025. 2025] [CDC. Antibiotic Resistance Threats in the United States, 2019. 2019] Table Table 1. Annual Infection Burden by Organism in the United States (Adapted From CDC and IDSA Estimates).

Antibiotic resistance remains a formidable threat to modern healthcare, undermining many advances of the antibiotic era. In response, antimicrobial stewardship programs have become a cornerstone of efforts to combat resistance and improve patient outcomes. The 2024 IDSA clinical guidance provides organism-specific recommendations for managing infections due to resistant pathogens. For example, the guidelines recommend carbapenems (eg, meropenem or imipenem-cilastatin) over piperacillin-tazobactam for serious infections caused by extended-spectrum β-lactamase–producing Enterobacterales and advocate the use of rapid molecular diagnostics to expedite targeted therapy.[43][44] Effective ASPs rely on an interprofessional team approach. Infectious disease clinicians, clinical pharmacists, microbiologists, infection control specialists, and information technology staff all collaborate to optimize antibiotic use in partnership with treating clinical teams. When well-implemented, stewardship programs result in more appropriate prescribing, lower rates of MDR organism infections and hospital-acquired infections, fewer antibiotic-related adverse events, shorter hospital stays, and reduced mortality.[43] Additionally, ASPs foster improved communication and shared decision-making among healthcare professionals and promote ongoing education in antimicrobial prescribing. Importantly, reducing unnecessary antibiotic exposure through stewardship is vital given the stagnation in new antibiotic development.[36] Collaboration with public health units and reference laboratories can yield further advances in the monitoring and surveillance of AMR trends within populations, including imported cases of MDR organisms across state and international borders. In summary, antimicrobial stewardship is critical to preserving the effectiveness of existing antibiotics. By tailoring therapies to current resistance patterns and strengthening interdisciplinary collaboration, stewardship programs help ensure that effective antimicrobial treatments remain available for future patients.[36]